Expert Insight: Impact of chromatography in peptide quantitation by hybrid LBA LC-MS/MS workflows

Join us on Friday, October 9, to learn about the importance of magnetic bead and chromatographic media selection for hybrid LBA/LC–MS/MS workflows

22 Sep 2020



Brian Rivera, Product Manager of Bioseparations and Specialty LC at Phenomenex

Traditional ligand binding assays (LBA) as a method for quantification of biotherapeutics in biologics matrices are being coupled with liquid chromatography tandem mass spectrometry (LC–MS/MS) to obtain more specificity and increase linear dynamic range (LDR), thus creating hybrid LBA/LC–MS/MS methods. This hybrid workflow is more sensitive and consistent than traditional methods, which is critical in efficacy and safety testing.

With the focus on sample preparation and mass spectrometry, LC is often overlooked. However, chromatographic optimization for hybrid LBA/LC-MS/MS methods step can ensure a robust analysis. In this webinar, Brian Rivera, Product Manager of Bioseparations and Specialty LC at Phenomenex, will discuss the importance of magnetic bead and chromatographic media selection for hybrid LBA/LC–MS/MS workflows.

Key Learning Objectives:

  • Basic overview of the new gold standard in pharmacokinetics for large molecule- hybrid LBA LC-MS
  • LC  development space for peptide quantitation methods
  • Improving robustness in sample preparation for peptide quantitation 

Who Should Attend?

  • Bionalytical chemists new to large molecule pharmacokinetics and biotransformation methods
  • Laboratories transitioning away from ligand binding assay to mass spectrometry
  • Anyone interested in practical sample preparation strategies to improve current LBA LC-MS/MS methods

This webinar will run on Friday, October 9, at:

  • 16:00 BST
  • 17:00 CEST
  • 08:00 PDT
  • 11:00 EDT

Register for this webinar here>>

SelectScience runs more than 10 webinars a month across various scientific topics, discover more of our webinars here>>